T1	intervention 28 53	lapatinib and vinorelbine
T2	control 57 68	vinorelbine
T3	eligibility 72 159	patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment
T4	No-of-participants 420 423	149
T5	outcome-Measure 634 682	progression-free survival (PFS) rate at 18 weeks
T6	outcome 792 812	PFS rate at 18 weeks
T7	intervention-value 836 841	45.9%
T8	control-value 845 850	38.9%
T9	outcome 863 866	ORR
T10	intervention-value 871 876	19.7%
T11	control-value 892 897	16.9%
T12	outcome 1091 1108	Toxicity profiles
